A reopening play, focussing on elective surgery, poised for growth.7 Jul 2021 22:17
Tissue Regenix is a pioneering medical devices company focussing on regenerative products. Having spent over £100 million researching, developing and gaining approval for a range of products in the USA and Europe, TRX has just completed an expansion programme which will enable the company to increase sales and revenue, just as elective surgery is resuming post-pandemic.
Led by a new CEO and CFO TRX is determined to commercialise it’s products. With a clear path forwards for growth the team are building on an existing set of strategic agreements to increase the uptake for TRX’s product range. With an increasing number of new white label and distribution agreements already in place, and the promise of more to come, TRX is moving in the right direction.
FAQ
So, if it’s that good, why are the shares trading at less than a penny?
TRX got caught up in the Woodford scandal and suffered when his fund collapsed. A fundraise by the company which followed pushed the sp lower still. Since then though there is a new team in place and funding is much more secure than it was.
Does it have enough cash to survive?
Like many biotech firms cashflow is important at the pre profit stage. TRX is no exception but the company is funded for at least the 18 months and has come successfully through the pandemic maintaining sales from 2019-20. Once elective surgery resumes cash flow will rapidly increase. Remember, the vast majority of surgeries can only be delayed, they can’t be cancelled indefinitely which gives TRX a solid market for it’s products.
What kind of market are we talking about?
Although based in Yorkshire (God’s own country) the company’s sales are predominately in the US but some UK sales also take place and there has been recent progress in making further agreements in Europe, most recently in Poland.
Further Research
Latest video of 2020 results from CEO and CFO
https://www.youtube.com/watch?v=VURo1glkV50
Hear what Gervaise Williams of Premier Miton has to say about the company
https://www.youtube.com/watch?v=6QdeB9B8mtE
Hardman reports
https://www.hardmanandco.com/research/
See news on Proactive for media updates
https://www.proactiveinvestors.co.uk/companies/news/904109/tissue-regenix-ready-to-build-on-strong-performance-through-pandemic-904109.html
Search on ‘linkedin’ for ‘Tissue Regenix’ for regular case studies by surgeons using TRX’s products and their feedback.